Impact of universal HIV treatment and dolutegravir on health outcomes in Africa
Long-term impact of universal treatment and dolutegravir on population HIV virologic and incidence outcomes in Africa: The LONGVIEW Study
This study is looking at how well HIV treatment, especially using a medicine called dolutegravir, works for people in Uganda, particularly during and after the COVID-19 pandemic, to see how it helps keep the virus under control and what challenges might come up.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10806956 on NIH RePORTER |
What this research studies
This research investigates how the universal treatment of HIV and the use of dolutegravir affect the health outcomes of populations in Africa, particularly in Uganda. It focuses on understanding the long-term effects of these treatments on viral load suppression and the incidence of HIV, especially in the context of disruptions caused by the COVID-19 pandemic. By analyzing data from a large cohort of HIV-positive individuals, the study aims to provide insights into the effectiveness of current treatment strategies and the challenges posed by drug resistance. Participants will be monitored over several years to assess changes in their health status and treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-positive individuals aged 15-49 living in southcentral Uganda.
Not a fit: Patients who are not HIV-positive or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for managing HIV treatment and reducing its incidence in affected populations.
How similar studies have performed: Previous research has shown promising results in similar approaches to HIV treatment and management, indicating potential for significant advancements.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Grabowski, Mary Kathryn — Johns Hopkins University
- Study coordinator: Grabowski, Mary Kathryn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.